Details for New Drug Application (NDA): 020142
✉ Email this page to a colleague
NDA 020142 describes CATAFLAM, which is a drug marketed by Amici Pharma and Novartis and is included in two NDAs. It is available from three suppliers. Additional details are available on the CATAFLAM profile page.
The generic ingredient in CATAFLAM is diclofenac potassium. There are forty-seven drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.
The generic ingredient in CATAFLAM is diclofenac potassium. There are forty-seven drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.
Summary for 020142
| Tradename: | CATAFLAM |
| Applicant: | Novartis |
| Ingredient: | diclofenac potassium |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Nov 24, 1993 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Nov 24, 1993 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
